A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sébert, Marie, Renneville, Aline, Bally, Cécile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, Marie-Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chermat, Fatiha, Sapena, Rosa, Nibourel, Olivier, Chaffaut, Cendrine, Chevret, Sylvie, Preudhomme, Claude, Adès, Lionel, Fenaux, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669173/
https://www.ncbi.nlm.nih.gov/pubmed/30733271
http://dx.doi.org/10.3324/haematol.2018.207118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669173/
https://www.ncbi.nlm.nih.gov/pubmed/30733271
http://dx.doi.org/10.3324/haematol.2018.207118

Ejemplares similares